Advanced search
Publication Cover
Journal of Chemotherapy Volume 32, 2020 - Issue 1
Submit an article Journal homepage
105
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

‘High’ antiretroviral deintensification strategy and cellular HIV DNA levels

Massimiliano LanzafameUnità Semplice Organizzativa “Diagnosi e Terapia dell’infezione da HIV”, University of Verona, Verona, Italy; View further author information
,
Emanuela LattuadaUnità Complessa di Malattie Infettive, University of Verona, Verona, Italy; Correspondence[email protected]
View further author information
,
Marcello VincenziUnità Complessa di Malattie Infettive, University of Verona, Verona, Italy; View further author information
,
Marta VecchiUnità Complessa di Malattie Infettive, University of Verona, Verona, Italy; ORCID Iconhttp://orcid.org/0000-0002-2917-4587View further author information
ORCID Icon,
Dora LuiseUnità Complessa di Malattie Infettive, University of Verona, Verona, Italy; View further author information
,
Erica DianiMicrobiology and Virology Section, Department of Diagnostic and Public Health, University of Verona, Verona, ItalyView further author information
&
Davide GibelliniMicrobiology and Virology Section, Department of Diagnostic and Public Health, University of Verona, Verona, ItalyView further author information
 show all
Pages 49-51 | Received 26 Jun 2019, Accepted 08 Nov 2019, Published online: 06 Dec 2019

References

  • Antiretroviral Therapy Cohort Colloboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–9.
  • Antiretroviral Therapy Cohort Colloboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–56.
  • Paton NI, Stohr W, Oddershede L, Arenas-Pinto A, Walker S, Schulper M, et al. The protease inhibitor monotherapy versus ongoing triple therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. Health Technol Assess. 2016;20:1–158.
  • Lanzafame M, Piacentini D, Lattuada E, Rizzardo S, Chiesi S, Vento S. “High” antiretroviral deintensification, a strategy to avoid drug interactions and unfavourable long-term effects of HAART. Infect Dis (Lond). 2018;50:788–90.
  • Avettand-Fènoël V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A, et al. Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications. Clin Microbiol Rev. 2016;29:859–80.
  • Christine R, Avettand-Fenoel V. Total HIV-DNA: a global marker of HIV persistence. Retrovirology. 2018; 5:30–6.
  • Minga AK, Anglaret X, d' Aquin Toni T, Chaix M-L, Dohoun L, Abo Y, et al. HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults. J Acquir Immune Defic Syndr. 2008;48:350–4.
  • Lanzafame M, Nicolè S, Rizzardo S, Piacentini D, Chiesi S, Lattuada E, et al. Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir. New Microbiol. 2018;41:262–7.
  • Avettand-Fenoel V, Flandre P, Chaix ML, Ghosn J, Delaugerre C, Raffi F, et al. MONARK Study Group. Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial. J Antimicrob Chemother. 2010;65:1005–7.
  • Lambert-Niclot S, Flandre P, Valantin M-A, Soulie C, Fourati S, Wirden M, et al. Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks. PLoS One. 2012;7:e41390.
  • Lombardi F, Belmonti S, Quiros-Roldan E, Latini A, Castagna A, D’Ettore G, et al. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of swithing to atazanavir/ritonavir + lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. J Antimicrob Chemoter. 2017;72:2055–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.